RegenxBio has unveiled positive one-year data from the Phase II ALTITUDE trial of ABBV-RGX-314 to treat diabetic retinopathy (DR) without center-involved diabetic macular oedema (CI-DME) using in-office suprachoroidal delivery.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,